# A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation

> **NIH NIH R41** · REBISCAN, LLC · 2020 · $225,000

## Abstract

Project Summary/Abstract
!
 Amblyopia is vision loss caused by neglect of a structurally normal eye due to
strabismus, asymmetric refraction (anisometropia), or deprivation. It is irreversible if not treated
by age 7, but half of all patients in the U.S. are undetected and untreated until after it is too late,
making it the leading cause of preventable vision loss. Rebion (Rebiscan, Inc) has developed
retinal birefringence scanning (RBS) into a commercial product, the RBS-based “blinq” device,
which detects amblyopia and strabismus with 94% accuracy, compared with 69% accuracy of
non-RBS methods.
 Although blinq effectively screens for strabismus and amblyopia by direct detection of
these conditions with very high sensitivity (97%), published “specificity” of the device is closer to
87%. Given the 5% prevalence of amblyopia and strabismus, this means that 2 normal patients
could potentially be referred for every treatable case. It is therefore essential that “specificity” of
blinq be improved if the device is to be adopted widely. One likely cause of false referrals is
corneal birefringence, which can interfere with an RBS test. Unlike retinal birefrigence, corneal
birefringence can vary greatly between patients and cause inaccurate RBS results. If corneal
birefringence could be neutralized as a factor in RBS, the specificity of the blinq device could
likely be improved to equal or exceed the device's 97% sensitivity.
 Leading researchers at Johns Hopkins University (JHU) have developed a novel,
patented approach that incorporates corneal birefringence compensation in an RBS system.
This approach can be readily optimized within blinq's current mechanical and electrical design.
In this Phase I study, we believe that by collaborating with the JHU research team, we will be
able to develop a new device that produces significant advantages over existing technologies,
including the commercially available blinq device.
 Applying JHU's research advancements to the FDA-cleared blinq device will allow rapid
commercial adoption of a breakthrough technology for detection of amblyopia. The improved
end result is that vision screening in the real world will immediately improve and save thousands
of children from unnecessary vision loss. Successful execution of this project will help improve
the quality of care and outcomes for thousands of children annually, while simultaneously
reducing the costs of care for all.

## Key facts

- **NIH application ID:** 9907989
- **Project number:** 1R41EY030382-01A1
- **Recipient organization:** REBISCAN, LLC
- **Principal Investigator:** Boris Gramatikov
- **Activity code:** R41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $225,000
- **Award type:** 1
- **Project period:** 2020-09-01 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9907989

## Citation

> US National Institutes of Health, RePORTER application 9907989, A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation (1R41EY030382-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9907989. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*